ASTRAZENECA PHARMA INDIA LTD. - 506820 - Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
This is to certify that Integrated Registry Management Services Private Limited, are the Company''s RTA and that all activities are in relation to the share transfer are maintained by them. We are also attaching the certificate received from our RTA. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith the Certificate dated April 5, 2024 issued by the RTA of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot
This is in reference to our letter dated March 6, 2024, enclosing therewith a Postal Ballot Notice dated February 8, 2024 seeking consent of the members of the Company through Special Resolution for appointment of Ms. Bhavana Agrawal (DIN: 10485441) as a Director and also as a Whole-time Director of the Company. In relation to the same, we are enclosing herewith the Voting results along with the Scrutinizer''s Report and the same are being placed on the Company''s website and website of National Securities Depository Limited.
AstraZeneca, Daiichi drug gets broad tumor approval in US
The US Food and Drug Administration cleared the medicine for patients who have HER2-positive solid tumors that have spread or can't be removed with surgery, the company said. These patients have already received prior treatment and don't have any good alternatives. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Summary Of Proceedings Of 44Th Annual General Meeting
In furtherance to your email dated April 6, 2024 and the enclosed summary of proceedings of 44th Annual General Meeting held on August 14, 2023, we wish to inform that that the 44th Annual General Meeting commenced at 3:00 PM and concluded at 4:45 PM (IST).
AstraZeneca Says Key Lung Cancer Drug Improved Survival
Lung cancer is the leading cause of cancer death among men and women, accounting for about 20% of all cancer deaths. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015
This is to inform that AstraZeneca Pharma India Limited has received permission to import for sale and distribution of Trastuzumab deruxtecan lyophilized powder for concentrate for solution for infusion 100mg (Enhertu) from Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India for the attached additional indications. AstraZeneca Pharma India appoints Vinay Sharma as business unit head
Currently, Sharma is a part of the Philippines country leadership team as Business Unit Head Respiratory and Immunology ASTRAZENECA PHARMA INDIA LTD. - 506820 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Appointment Of Senior Management Personnel
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Mr. Vinay Sharma as Business Unit Head - Rare Disease unit with effect from July 1, 2024.
AstraZeneca To Buy Fusion Pharma For Up To $2.4 Billion
Shares of Astra were little changed in early London trading on Tuesday. They are down around 5% over the last 12 months.